http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Bioventus to Present at the Morgan Stanley Global Healthcare Conference
-
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
-
Bioventus (BVS) Receives FDA 510(k) Clearance for SonaStar Elite
-
Bioventus Receives FDA 510(k) Clearance for SonaStar Elite
-
Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022
-
Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance
-
Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis
-
Bioventus (BVS) Reports Prelim Q1 Sales of $116.5M-$118.5M, Adjusted EBITDA of ($19.4M)-($19M)
-
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA
-
Bioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
-
Bioventus (BVS) TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives
-
Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives
-
Bioventus Announces Inducement Equity to SVP Chief Financial Officer Mark Singleton
-
Bioventus (BVS) Exercises Call Option to Acquire CartiHeal
-
Bioventus Exercises Call Option to Acquire CartiHeal
-
Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference
-
Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance
-
Bioventus Receives 510(k) Clearance for StimRouter Pain Management Device
-
Bioventus (BVS) Appoints Mark Singleton as CFO
-
Bioventus Appoints Mark Singleton as Chief Financial Officer
-
Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022
-
Bioventus (BVS) Prelim. Q4 Revenue Tops Consensus
-
Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue
-
Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Bioventus Appoints Michelle McMurry-Heath to Board of Directors
-
Bioventus (BVS) Granted US FDA Clearance for BoneScalpel Access
-
Bioventus Receives US FDA Clearance for BoneScalpel® Access™
-
Bioventus to Expand Operations and Manufacturing in Memphis
-
Bioventus (BVS) Announces CFO to Step Down
-
Bioventus Announces Chief Financial Officer Transition Plan
-
Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance
-
Sharon Klugewicz Joins Bioventus as Senior Vice President, Quality and Regulatory Affairs
-
Bioventus Completes the Acquisition of Misonix
-
Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021
-
Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus
-
BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration
-
DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons
-
Bioventus (BVS) Proceeds with Option Agreement to Acquire CartiHeal
-
Bioventus Proceeds with Option Structure Agreement with CartiHeal
-
Bioventus Invests in Trice Medical Minimally Invasive Technologies
-
Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer
-
Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance
-
Bioventus (BVS) Acquires Misonix (MSON) for $28/sh
-
Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix
-
Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance
-
Bioventus® Management to Present at Canaccord Genuity Growth Conference and Morgan Stanley Virtual Global Healthcare Conference
-
Bioventus (BVS) Appoints Mary Kay Ladone to its Board
-
Bioventus Appoints Mary Kay Ladone to Board of Directors
-
Bioventus Launches OSTEOAMP® SELECT Flowable Nationwide
-
Bioventus (BVS) Announces Investment in Vaporox

